AngioDynamics (ANGO) Misses Q3 EPS by 2c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance
March 30, 2023 7:00 AM EDTFiscal Year 2023 Third Quarter Highlights
Net sales of $80.7 million increased 9.1% compared to the prior-year quarter Med Tech net sales of $22.9 million increased 16.6% Med Device net sales of $57.8 million increased 6.4% Gross margin of 50.2% decreased 200 basis points year over year GAAP loss per share of $0.24 and adjusted loss per share of $0.03LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on... More
